Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies

Stock Information for Gamida Cell Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gamida Cell Ltd.

XORTX Welcomes New Member to the Board of Directors
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Gamida Cell Actively Pursuing Strategic Alternatives
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.